FY2024 EPS Estimates for AC Immune Raised by Leerink Partnrs

AC Immune SA (NASDAQ:ACIU) – Analysts at Leerink Partnrs boosted their FY2024 earnings per share estimates for shares of AC Immune in a research note issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings of ($0.57) per share for the year, up from their prior estimate of ($0.60). The consensus estimate for AC Immune’s current full-year earnings is ($0.63) per share. Leerink Partnrs also issued estimates for AC Immune’s Q4 2024 earnings at ($0.19) EPS, FY2025 earnings at ($0.83) EPS and FY2026 earnings at ($0.55) EPS.

Separately, HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of AC Immune in a research note on Friday, November 15th.

AC Immune Stock Up 1.9 %

AC Immune stock opened at $2.75 on Friday. The stock has a market cap of $272.09 million, a PE ratio of -5.98 and a beta of 1.29. AC Immune has a 12-month low of $2.25 and a 12-month high of $4.98. The business’s 50-day moving average price is $2.88 and its two-hundred day moving average price is $3.18.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. grew its position in AC Immune by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock worth $72,000 after acquiring an additional 7,400 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of AC Immune during the second quarter worth about $218,000. Finally, Geode Capital Management LLC increased its stake in shares of AC Immune by 6.4% in the third quarter. Geode Capital Management LLC now owns 58,296 shares of the company’s stock valued at $220,000 after buying an additional 3,499 shares during the period. 51.36% of the stock is currently owned by institutional investors.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.